Category Archives: Cardiac Regeneration

Scientists have developed a new technique that can repair and even regenerate heart muscle cells after a heart attack (or myocardial infarction). While it has only been tested on mice so far, if it works the same in humans it could potentially be a life-saving treatment for people who have suffered a heart attack. The technique uses a synthetic messenger ribonucleic acid (mRNA).mRNA creates a 'blueprint' of DNA sequences that the body then uses to build the proteins that form and regulate our cells.By tweaking the mRNA, scientists can deliver different instructions for different biological processes. Continue reading →

A paper recently published in the journal Biomaterials reviewed the new advances in three-dimensional bioprinting (3DBP) for regenerative therapy in different organ systems. Study:Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models Continue reading →

The Yoga Sutras of Patanjali, considered to be a collective authoritative text on the practice and philosophy of yoga, were compiled by the sage Patanjali at least 1,700 years ago. They outline the eight limbs of yoga, which teach us the ways in which one can live a yogic life. They also describe the result of a regular and dedicated practice and how one can achieve that goal Continue reading →

Cambridges 4basebio Plc and Italian company Heqet Therapeutics have formed a joint venture to develop a non-viral vector therapy for cardiac regeneration. 4basebio is a life sciences group focused on exploiting IP in the field of cell and gene therapies and DNA and mRNA vaccines; HeqetvTherapeutics isa Kings College London biotech spin-out developing novel RNAi therapeutics to reverse the damage created by ischemic heart disease. The new JDA is focused on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration and treatment of myocardial infarction more broadly. Continue reading →

ROCKVILLE, Md., May 4, 2022 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, is reporting that researchers have demonstrated the therapeutic efficacy of Thymosin Beta 4 (T4) as a combination treatment against hyperglycemia (diabetic)-induced changes in human corneal epithelial cells. "Our study elucidates for the first time that a T4 and vasoactive intestinal peptide (VIP) combo treatment plays a crucial role in regulating the tight junction stability and cytoskeleton rearrangement [of the cornea], which are closely related to barrier integrity Continue reading →

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics, Inc. Continue reading →